about
Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synucleinAstrocytic β2 Adrenergic Receptor Gene Deletion Affects Memory in Aged Mice.Absence of system xc- on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis.Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor.Are vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy?Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.The Proteasome Inhibition Model of Parkinson's Disease.Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed.Neuropeptide FF receptors as novel targets for limbic seizure attenuation.MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.Lack of effect of Theiler's murine encephalomyelitis virus infection on system xc⁻.High-affinity Na+/K+-dependent glutamate transporter EAAT4 is expressed throughout the rat fore- and midbrain.Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc.6 Hz corneal kindling in mice triggers neurobehavioral comorbidities accompanied by relevant changes in c-Fos immunoreactivity throughout the brain.In-depth behavioral characterization of the corticosterone mouse model and the critical involvement of housing conditions.Absence of system xc- in mice decreases anxiety and depressive-like behavior without affecting sensorimotor function or spatial vision.Slc7a11 (xCT) protein expression is not altered in the depressed brain and system xc- deficiency does not affect depression-associated behaviour in the corticosterone mouse model.The cystine-glutamate exchanger (xCT, Slc7a11) is expressed in significant concentrations in a subpopulation of astrocytes in the mouse brain.Plastic changes at corticostriatal synapses predict improved motor function in a partial lesion model of Parkinson's disease.Disruption of the HPA-axis through corticosterone-release pellets induces robust depressive-like behavior and reduced BDNF levels in mice.Altered vesicular glutamate transporter expression in human temporal lobe epilepsy with hippocampal sclerosis.Validation of the 6 Hz refractory seizure mouse model for intracerebroventricularly administered compounds.Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease.Genetic deletion of xCT attenuates peripheral and central inflammation and mitigates LPS-induced sickness and depressive-like behavior in mice.Dopaminergic neurons of system x(c)⁻-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity.Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinson's DiseaseSystemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathwayGenetic and pharmacological manipulation of glial glutamate transporters does not alter infection-induced seizure activityAnticonvulsant and antiepileptogenic effects of system xc- inactivation in chronic epilepsy models
P50
Q30633819-78BD3601-EC67-4319-ADC2-7CA57CD0ACF6Q36173083-8E67A36C-7CD8-4262-8608-F68BBC73466BQ37586538-E5D23AD3-60AE-4F86-9B7E-0F10FE2A90D4Q37729142-6E1B848D-4D7A-4431-B9A9-34952FE71571Q38134724-C75A92DB-EF40-4884-AB10-18C673C2AC20Q38580123-AE67C18A-8411-493D-8651-5E6D411096C5Q38996038-1E4DE33A-856F-40E1-A02B-4C9D5BD2DF65Q40400682-DCDC92BA-5629-4A56-9A65-FA8E668814ECQ40950852-E082A257-5B9E-48D2-911A-04FEC22816B0Q41232424-E7820298-4D90-4525-9954-0665561E4646Q41398493-00C933BF-3D8D-40B8-ACAF-771FB502D1A6Q42441248-1ED65912-3C02-40A9-A137-44E62AB5D513Q42503524-F257680C-D5DF-4535-A470-90257E893105Q47213168-CB376EB9-2D3A-4A1A-A2C1-10FF00858CA8Q47585703-CEB66795-BAD2-4114-8003-A9A2A0ECD93FQ47683896-54C7564A-4A53-4AD5-88B5-0DC9542038D4Q47775588-0059F200-A9A6-4206-8116-6CE362AB36B6Q47852091-CA6B44E5-7B54-4CB8-B4A9-6AC672EBA6FBQ47962017-E615B5FD-6BA4-4BDA-B8AF-10A1633DCBB5Q48054792-3EDB05EA-ED2E-4C5A-8B02-8BC31EF9EDEAQ48335704-D3D8E725-5C91-48BA-AC76-7038F81D8D62Q51830195-37A51C07-2310-4633-86CF-15E932B7DE72Q52152099-4CA251CA-7766-490A-B258-DD41E32CA111Q52564304-4CDFBE39-E607-4F62-8B35-A01DEEE0DF3EQ55463544-5EBA4D17-96FF-4558-8862-AEA3B9D3E44AQ57072471-B2EC0628-1B61-418B-A4CA-BC47C1E9027CQ90766342-47D0B418-3974-4914-9FD4-7B4EC4515C1CQ91511367-9C4E7F07-64D1-467E-8483-6FEE7DC08964Q92622206-9BCE5A7A-9DCC-4443-9794-5AAF9D1178F7
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ann Massie
@en
Ann Massie
@nl
type
label
Ann Massie
@en
Ann Massie
@nl
prefLabel
Ann Massie
@en
Ann Massie
@nl
P31
P496
0000-0002-8418-5879